ADC Therapeutics SA (ADCT) Tops Q1 EPS by 34c

ADC Therapeutics SA (NYSE: ADCT) reported Q1 EPS of ($0.36), $0.34 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $46.5 million versus the consensus estimate of $28.94 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
• VNET Group (VNET) Misses Q2 EPS by 164c
• Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded